Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

Inclusion Criteria: * histologically or cytologically confirmed local advanced unresectable/metastatic adenocarcinoma of biliary tract * measurable disease * available tumor tissue for investigational immunohistochemical evaluations * ECOG PS 0-2 * No prior chemotherapy, biologic therapy or radiation therapy * Age Eighteen and older * Lab values per protocol Exclusion Criteria: * Life expectancy less than three months * Concurrent use of chemotherapy not indicated in the study protocol or any other investigational agents and patients who have received investigational drugs less than four weeks prior to enrollment * Prior therapy, which affects or targets the EGF pathway * Treatment for other carcinomas within the last five years, except cured non-melanoma skin and treated in-situ cervical cancer * Recovery from major surgery within three weeks of the start of study treatment